Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vir Biotechnology, Inc. (VIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results – Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform –"
02/23/2023 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results – Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 – – Strong balance sheet expected to fund Vir’s robust portfolio through major inflection points with the flexibility to evaluate external opportunities – SAN FRANCISCO, FEBRUARY 23, 2023"
08/09/2022 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results – More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years – – Company provides update on COVID-19 development program and outlines multiple anticipated value drivers from its robust pipeline – SAN FRANCISCO, August 9, 2022"
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results – To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized – – Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD, and initial HIV vaccine immunology data –"
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "Revenues: Total revenues for the quarter ended September 30, 2020 were $1.9 million, compared to $1.4 million for the same period in 2019. The increase for the quarter was primarily due to the timing of research activities under the HIV and TB grants with the Bill & Melinda Gates Foundation. 3 ● Research and Development Expenses: Research and development expenses were $70.7 million for the quarter ended September 30, 2020, which includes $4.2 million of non-cash stock-based compensation expense, compared to $39.9 million for the same period in 2019, which included $0.9 million of non-cash stock-based compensation expense. The increase for the quarter was primarily due to contract manufacturing expenses for our SARS-CoV-2 programs, higher fair value of our contingent consideration due..."
08/11/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
Docs: "Revenues: Total revenues for the quarter ended March 31, 2020 were $5.7 million, compared to $3.7 million for same period in 2019. The increase for the quarter was primarily due to an increase in grant revenue. • Research and Development Expenses: Research and development expenses were $65.0 million for the quarter ended March 31, 2020, which includes $1.5 million of non-cash stock-based compensation expense, compared to $25.9 million for the same period in 2019, which includes $0.4 million of non-cash stock-based compensation expense. The increase for the quarter was primarily due to an increase in collaboration expenses, personnel, and ongoing clinical expenses relating to VIR-2482 and VIR-3434. • General and Administrative Expenses: General and administrative expenses were..."
03/26/2020 8-K Quarterly results
Docs: "Revenues: Total revenues for the quarter ended December 31, 2019 were $1.0 million, compared to $3.1 million for same period in 2018. Total revenues for the year ended December 31, 2019 were $8.1 million, compared to $10.7 million for the same period in 2018. The decreases for the quarter and full year were primarily due to a decline in grant revenue. • Research and Development Expenses: Research and development expenses were $52.9 million for the quarter ended December 31, 2019, which includes $1.1 million of non-cash stock-based compensation expense, compared to $22.0 million for the same period in 2018, which includes $0.3 million of non-cash stock-based compensation expense. For the year ended December 31, 2019, research and development expenses were $148.5 million, which includ..."
11/19/2019 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy